EGFR and neoplasm: In the phase Ib TATTON trial, 64% of patients with EGFR mutation-positive NSCLC and MET-amplified tumours (MET/CEP7 ratio ≥ 2 or mean GCN ≥ 5) progressing on first-generation EGFR TKI responded to savolitinib plus osimertinib [126].